Research advances of rituximab resistance in B-cell non-Hodgkin lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 312-314, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-475217
ABSTRACT
Anti-CD20 monoclonal antibody rituximab has become an essential component of treatment regimens for B-cell non-Hodgkin lymphoma(NHL).It is routinely incorporated into all phases of conventional treatment of B-cell NHL,but the precise mechanisms of action of rituximab in human remain unknown.This article will clarify the mechanisms of action of rituximab,the incidence and potential mechanisms of resistance.Finally,the novel approaches to modulate the antibody,the tumor cell,and the host immunologic environment to overcome rituximab resistance are discussed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS